MET and non-small cell lung carcinoma: Both capmatinib and tepotinib are FDA-approved for treatment of patients with MET exon 14 skipping mutant metastatic NSCLC, and recent studies report promising intracranial responses to both agents in patients with this mutation (44, 45).